Table 2. Overview of GANT61 treatment in animal models.
| Tumor type | Animal model | Dose | Formulation | Treatment duration | Efficacy | Ref. |
|---|---|---|---|---|---|---|
| Prostate | 22Rv1 xenograft (BALB/c nude (nu/nu) mice) |
50mg/kg | Every other day (s.c. injection) |
16 days | Tumor regression until no tumor palpable | 58 |
| Neuroblastoma | SK-N-AS xenograft (NMRI-nu/nu mice) |
50mg/kg | Daily (gavage) |
12 days | Tumor growth reduction (63% of control) | 67 |
| Pancreas | Pancreatic CSC xenograft (humanized NOD/SCID IL2γ null mice) |
40mg/kg | 3 times/week (i.p. injection) |
6 weeks | CSC tumor growth inhibition | 68 |
| Hepatocellular | Huh7 xenograft (SCID mice) |
50mg/kg | Every other day (i.p. injection) |
4 weeks | Tumor growth reduction | 104 |
| Lung | NCI-H520, NCI-H2170 and NCI-H226 xenograft (immune deficient Rag1−/− mice) |
50mg/kg | Every other day (i.p. injection) |
20 days | Tumor growth reduction | 79 |
| Rhabdomysarcoma | RD, RH30 xenograft (athymic nu/nu mice) |
50mg/kg | 3 times/week (i.p. injection) |
Until tumor size control mice >1cm3 (21-33 days) |
Tumor growth reduction (53% in RD and 47% in RH30 cells compared to control) | 77 |
| Embryonal rhabdomyosarcoma | CCA, Rh36 and A673 cells introduced in Chick chorioallantantoic membrane (CAM) assay |
10μM /30μM | Pre-mixture of cells with GANT61 | 7 days | Decreased tumor volume | 106 |